← All trials
NCT06921213
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jun 30, 2027
- First posted
- Apr 10, 2025
- Last posted
- May 4, 2025
- Enrollment
- 90
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- University of LondonOfficial
- National University of IrelandCollaborator
- University of SydneyCollaborator
- Medical Research CouncilCollaborator
- National University of IrelandOfficial
- Chiangmai UniversityCollaborator
- Murdoch UniversityCollaborator
- Stellenbosch UniversityCollaborator
- Wellcome TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.